- Sales increased 20% and EBITDA increased 52% vs. prior year quarter -

- 2016 financial guidance reaffirmed -

- Conference call at 8:30 a.m. ET on April 29, 2016 -

EAST RUTHERFORD, N.J., April 29, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM) reports results for the first quarter ended March 31, 2016.

Highlights

- Sales increased 20%, and 21% excluding the impact of foreign currency, to $93.9 million compared to $78.2 million in the same quarter last year.  

- Adjusted EBITDA increased 52% to $27.2 million compared to $18.0 million in the same quarter last year. (See table at the end of this release).     

- GAAP Diluted EPS from continuing operations was $0.45 compared to $0.26 in the same quarter last year and Adjusted Diluted EPS was $0.50 compared to $0.29 in the same quarter last year.

- Net cash was $85.6 million at the end of the first quarter, an improvement of $71.6 million during the quarter.

- The Company continues to expect full year 2016 sales, excluding the impact of foreign currency, to increase between 8% and 12% compared to 2015.  Adjusted EBITDA is still expected to be between $142 and $148 million, a 10% to 15% increase over 2015.  (See Financial Expectations section below).

“We are pleased to report a very positive first quarter and confirm our full year expectations for strong, profitable growth.  We saw growth across all product categories, especially controlled substances, where we continue to be favorably positioned to take advantage of market dynamics,” commented Steven M. Klosk, President and Chief Executive Officer of Cambrex. “Overall industry trends remain favorable and we are adding resources and executing on various capital projects to ensure we continue to have capacity to satisfy demand.

“We now expect the new large scale capacity project at our Charles City, Iowa facility to come on line around the end of the second quarter of this year.  While delays in equipment delivery and a few installation challenges caused us to push the start-up date back a few months, we successfully adjusted the site’s production schedule to ensure that we continue to meet customer demand and the expected cost of the project remains on budget.”

Basis of Reporting
The Company has provided a reconciliation of GAAP amounts to adjusted (i.e. Non-GAAP) amounts at the end of this press release.  Cambrex management believes that the adjusted amounts provide useful information to investors due to the magnitude and nature of certain expenses recorded in the GAAP amounts.

First Quarter 2016 Operating Results – Continuing Operations
Sales were $93.9 million, compared to $78.2 million in the same period last year, representing a 20% increase.  Foreign exchange unfavorably impacted reported sales growth by 1%.  The sales increase primarily reflects higher volumes of controlled substances, certain branded active pharmaceutical ingredients (APIs) and generic APIs, partially offset by lower pricing. 

Gross margins increased to 41% from 37% compared to the same quarter last year.  The increase reflected a favorable mix of products and higher plant utilization.  Foreign currency favorably impacted margins by 2% in the first quarter of 2016.

Selling, general and administrative expenses were $14.0 million compared to $13.8 million in the same quarter last year.  The increase was mainly due to costs related to the implementation of a new ERP system partially offset by a favorable impact from foreign exchange.

Operating profit increased to $21.4 million from $12.7 million in the same quarter last year. The increase in operating profit was primarily the result of higher gross profit, partially offset by higher operating expenses.  Adjusted EBITDA was $27.2 million compared to $18.0 million in the same quarter last year. 

Income tax expense was $6.6 million resulting in an effective tax rate of 31%, compared to expense of $3.8 million in the same period last year. The effective tax rate was flat compared to the same quarter last year.

Income from continuing operations was $14.8 million or $0.45 per share compared to $8.4 million or $0.26 per share in the same quarter last year.  Adjusted income from continuing operations was $16.3 million or $0.50 per share, compared to $9.2 million or $0.29 per share in the same quarter last year (see table at the end of this release).

Capital expenditures and depreciation were $18.1 million and $5.4 million, respectively, compared to $12.0 million and $5.1 million, respectively, in the same quarter last year.

The improvement in net cash of $71.6 million during the first quarter of 2016 includes an advance payment of $39.0 million that is expected to reverse in 2020 and an advance payment of $21.0 million that is expected to reverse during the second quarter of 2016.

Financial Expectations – Continuing Operations
The following table shows the Company’s current expectations for its full year 2016 financial performance:

			Expectations
	Gross sales increase		8% - 12%
	Adjusted EBITDA		$142 - $148 million
	Adjusted income from continuing operations per share		$2.46 - $2.58
	Free cash flow		$60 - $70 million
	Capital expenditures		$70 - $75 million
	Depreciation		$26 - $28 million
	Effective tax rate		32% - 34%

Consistent with prior guidance for the full year 2016, these financial expectations are for continuing operations and exclude the impact of any potential acquisitions, divestitures, restructuring activities, outcomes of tax disputes and any charges related to any future sale of the Company’s Zenara business located in Hyderabad, India.  Sales expectations exclude the impact of foreign exchange.  EBITDA, Adjusted EBITDA and Adjusted income from continuing operations per share for 2016 will be computed on a basis consistent with the reconciliation of the first quarter 2016 results in the tables at the end of this release.  Free cash flow is defined as the change in debt, net of cash during the year.  The tax rate will be sensitive to the Company’s geographic mix of income.  

The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company’s first quarter 2016 Form 10-Q is filed with the SEC.

Conference Call and Webcast
A conference call to discuss the Company’s first quarter 2016 results will begin at 8:30 a.m. Eastern Time on April 29, 2016 and can be accessed by calling 1-800-768-6544 for domestic and +1-785-830-7990 for international.  Please use the passcode 2458958 and call approximately 10 minutes prior to the start time.  A webcast will be available in the Investors section on the Cambrex website located at www.cambrex.com.  A telephone replay of the conference call will be available through May 6, 2016 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the passcode 2458958 to access the replay. 

About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients (“APIs”), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.  Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.  

Forward Looking Statements 
This document contains “forward-looking statements,” including statements or tables regarding expected performance, especially those set forth under the heading “Financial Expectations – Continuing Operations,” “Highlights” and those attributed to our President and Chief Executive Officer in this document.  These and other forward looking statements may be identified by the fact that they use words such as “guidance,” “expects,” “anticipates,” “intends,” “estimates,” “believes” or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company’s Annual Report on Form 10-K for the period ended December 31, 2015, captioned “Risk Factors,” or otherwise described in the Company’s filings with the SEC provide examples of such risks and uncertainties that may cause the Company’s actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, market acceptance and adoption rate of our customers’ products, government legislation and regulations (including those pertaining to environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation, environmental matters, changes in foreign exchange rates, uncollectible receivables, the timing of orders or shipments and the Company’s ability to meet its production plan and customer delivery schedules, expected timing of completion of capacity expansions, loss on disposition of assets, the Company’s ability to dispose of Zenara assets held for sale, cancellations or delays in renewal of contracts, lack of suitable raw materials, the Company’s ability to receive regulatory approvals for its products, continued demand in the U.S. for late stage clinical products and the successful outcome of the Company’s investment in new products.

For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2015, including the Forward-Looking Statement sections therein, and other filings with the SEC.  The Company cautions investors and potential investors not to place significant reliance on the forward-looking statements contained in this press release and to give careful consideration to the risks and uncertainties listed above and contained in our SEC filings. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.

Use of Non-GAAP Financial Measures
EBITDA, Adjusted EBITDA and Adjusted Income from Continuing Operations are non-GAAP financial measures.  The Company defines EBITDA as operating profit plus depreciation and amortization expense and Adjusted EBITDA excludes the impact of any potential acquisitions, restructuring activities and charges related to any future sale or closure of the Company’s Zenara business located in Hyderabad, India.  Adjusted Income from Continuing Operations is calculated in a manner consistent with that shown in the table at the end of this release.  Other companies may have different definitions of EBITDA, Adjusted EBITDA and Adjusted Income from Continuing Operations. Therefore, these measures may not be comparable with non-GAAP financial measures provided by other companies.  EBITDA, Adjusted EBITDA and Adjusted Income from Continuing Operations should not be considered alternatives to measurements required by U.S. GAAP, such as net income or operating profit, and should not be considered a measure of Cambrex’s liquidity.  Cambrex uses EBITDA, Adjusted EBITDA and Adjusted Income from Continuing Operations among several other metrics to assess and analyze its operational results and trends.  Cambrex also believes EBITDA, Adjusted EBITDA and Adjusted Income from Continuing Operations are useful to investors because they are common operating performance metrics as well as metrics routinely used to assess potential enterprise value.  Cambrex has provided a reconciliation of U.S. GAAP amounts to non-GAAP amounts at the end of this press release.

CAMBREX CORPORATION
Statements of Profit and Loss
For the Quarters Ended March 31, 2016 and 2015
(in thousands, except per-share data)
			2016									2015
						% of									% of
		Amount				Sales					Amount				Sales
Gross Sales	$		93,935							$		78,184
Commissions, Allowances and Rebates			503									451
Net Sales			93,432									77,733
Other			1,309									(208	)
Net Revenues			94,741									77,525
Cost of Goods Sold			55,842				59.4	%				48,446				62.0	%
Gross Profit			38,899				41.4	%				29,079				37.2	%
Operating Expenses:
Selling, General and Administrative Expenses			14,045				15.0	%				13,751				17.6	%
Research and Development Expenses			3,478				3.7	%				2,655				3.4	%
Total Operating Expenses			17,523				18.7	%				16,406				21.0	%
Operating Profit			21,376				22.8	%				12,673				16.2	%
Other Expenses/(Income):
Interest (Income)/Expense, Net			(55	)								476
Other Expenses, Net			34									62
Income Before Income Taxes			21,397				22.8	%				12,135				15.5	%
Provision for Income Taxes			6,552									3,767
Income from Continuing Operations	$		14,845				15.8	%		$		8,368				10.7	%
Loss from Discontinued Operations, Net of Tax			(263	)								(375	)
Net Income	$		14,582				15.5	%		$		7,993				10.2	%
Basic Earnings/(Loss) per Share of Common Stock:
Income from Continuing Operations	$		0.47							$		0.27
Loss from Discontinued Operations, Net of Tax	$		(0.01	)						$		(0.01	)
Net Income	$		0.46							$		0.26
Diluted Earnings/(Loss) per Share of Common Stock:
Income from Continuing Operations	$		0.45							$		0.26
Loss from Discontinued Operations, Net of Tax	$		(0.01	)						$		(0.01	)
Net Income	$		0.44							$		0.25
Weighted Average Shares Outstanding
Basic			31,886									31,198
Diluted			32,771									32,158

CAMBREX CORPORATION
Consolidated Balance Sheets
As of March 31, 2016 and December 31, 2015
(in thousands)
		March 31,			December 31,
Assets		2016			2015
Cash and Cash Equivalents	$	85,597		$	43,974
Trade Receivables, Net		47,316			90,920
Other Receivables		9,558			7,278
Inventories, Net		131,607			109,920
Prepaid Expenses and Other Current Assets		9,717			7,187
Total Current Assets		283,795			259,279
Property, Plant and Equipment, Net		203,616			186,487
Goodwill		33,196			32,063
Intangible Assets, Net		7,291			6,691
Deferred Income Taxes		14,758			19,259
Other Non-Current Assets		1,546			1,760
Total Assets	$	544,202		$	505,539
Liabilities and Stockholders' Equity
Accounts Payable	$	39,345		$	39,257
Deferred Revenue and Advance Payments		27,179			16,298
Accrued Expenses and Other Current Liabilities		38,004			44,247
Short-Term Debt		-			30,000
Total Current Liabilities		104,528			129,802
Advance Payments		39,000			-
Deferred Income Taxes		7,872			7,735
Accrued Pension Benefits		42,890			42,661
Other Non-Current Liabilities		14,840			14,506
Total Liabilities	$	209,130		$	194,704
Stockholders’ Equity	$	335,072		$	310,835
Total Liabilities and Stockholders’ Equity	$	544,202		$	505,539

CAMBREX CORPORATION
Reconciliation of GAAP to non-GAAP Results
For the Quarters Ended March 31, 2016 and 2015
(in thousands)
	First Quarter 2016				First Quarter 2015
Operating Profit	$	21,376			$	12,673
Restructuring Expenses		290				-
Adjusted Operating Profit		21,666				12,673
Depreciation and Amortization		5,578				5,297
Adjusted EBITDA	$	27,244			$	17,970

				First Quarter 2016					First Quarter 2015
							Diluted EPS					Diluted EPS
Income from Continuing Operations				$	14,845	$	0.45		$	8,368	$	0.26
Restructuring Expenses					290		0.01			-		-
Stock-Based Compensation, Net of Tax 1					998		0.03			700		0.02
Amortization of Purchased Intangibles					176		0.01			169		0.01
Adjusted Income from Continuing Operations				$	16,309	$	0.50		$	9,237	$	0.29
1  Tax rate estimated at 35% for stock-based compensation.

Contact: Gregory P. Sargen                          
Executive Vice President & CFO                                 
Phone: 201-804-3055                                          
Email: gregory.sargen@cambrex.com       

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.